The 11th International Symposium on Targeted-Alpha-Therapy (TAT 11) continues the series of successful symposia on this topic that was initiated in 1997 by the Joint Research Centre of the European Commission. TAT 11 will provide information on the newest developments in preclinical studies, clinical experiences, dosimetry and instrumentation, quality assurance, regulatory, targeting, radiochemistry, and nuclide production and supply. Participate in the latest discussions, scientific exchange and in focused networking with industry leaders from around the world.
With targeted-alpha-therapy treatments beginning to hit the market, the clinical perspective has become an essential part of the TAT conversation. That is why TAT 11 will include the first ever Clinical Day on Thursday, April 4, with a single track of presentations featuring the world’s top clinical experts who will address the challenges and opportunities presented by targeted-alpha-therapies.